The ventricular assist device market size has grown rapidly in recent years. It will grow from $1.92 billion in 2023 to $2.18 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. Historical growth can be attributed to the increased prevalence of heart failure and a heightened demand for organ transplantation procedures.
The ventricular assist device market size is expected to see rapid growth in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. Forecasted growth is due to increased demand for destination therapy, an aging population, higher healthcare spending, and greater awareness of heart failure treatments. Key trends include extending VAD lifespan, device miniaturization, advanced pump tech, improved safety/efficacy, reduced side effects, and percutaneously inserted VADs.
The surge in cardiovascular disorders globally is a driving force behind the expansion of the ventricular assist device market. Cardiovascular disorders, stemming from factors such as high blood pressure, smoking, high cholesterol, and inactivity, are on the rise. Noncontagious diseases such as diabetes, chronic respiratory illnesses, and heart attacks linked to hypertension contribute to the escalating prevalence of cardiovascular disorders. This trend underscores the heightened demand for ventricular assist devices, serving as crucial support systems for severely ill cardiac patients. For instance, in 2021, the World Health Organization reported that India was anticipated to account for one-fifth of global deaths from stroke and ischemic heart disease, particularly affecting younger adults. Moreover, projections indicate that around 12.1 million people in the U.S. are expected to experience atrial fibrillation (A-Fib) by 2030. The mounting prevalence of cardiovascular disorders is poised to drive significant demand for ventricular assist devices in the forecast period.
The increased awareness surrounding heart failure treatment is a pivotal factor expected to fuel the growth of the ventricular assist device market. Heart failure, characterized by the heart's diminished ability to effectively pump blood, can result from conditions such as coronary artery disease, heart attacks, high blood pressure, and heart muscle damage. The escalating awareness about heart failure treatments is anticipated to drive the adoption of ventricular assist devices as a means to address heart failure. Notably, the American Heart Association projects a 46% increase in heart failure diagnoses by 2030, surpassing 8 million individuals affected. As the number of people diagnosed with heart failure continues to rise, the heightened awareness of available treatment options is poised to be a key driver for the ventricular assist device market.
Technological advancements stand out as a prominent trend gaining traction in the ventricular assist device market. Companies within the ventricular assist device sector are directing their efforts toward the development of next-generation devices that enhance blood circulation. Key industry players are prioritizing the creation of ventricular assist devices with innovative technologies to gain a competitive advantage and fortify their market positions. An illustrative example is the initiative by CorWave, a France-based medical technology company, in 2021. CorWave successfully developed left ventricular assist device (LVAD) membrane pump technology. This LVAD membrane pump employs a pulse pump, utilizing electromagnetic pulses rather than a rotary pump, to facilitate blood movement, closely mimicking the natural pulsatile action of the heart.
The adoption of percutaneously inserted ventricular assist devices is gaining prominence in the market. Percutaneously inserted ventricular assist devices are non-pulsatile axial flow pumps positioned across the aortic valve, pumping blood from the left ventricle. These devices alleviate the load on the left ventricle, decrease myocardial oxygen consumption, enhance cardiac output, and reduce left ventricular end-diastolic pressure. As an example, in August 2022, Abiomed Inc., a US-based medical device company, introduced the Impella, a percutaneous VAD designed for eligible pediatric patients in the USA. The Impella device provides effective cardiac support to compensate for a failing left ventricle and can serve as an alternative to extracorporeal membrane oxygenation (ECMO) or complement other therapies to enhance hemodynamics.
In August 2022, Medtronic PLC, an Ireland-based medical device company, acquired Affera, Inc. for $925 million. This strategic acquisition broadens Medtronic's portfolio of cardiac ablation products, introducing their initial cardiac mapping and navigation platform. The platform includes radiofrequency ablation, focal pulsed field, and an integrated diagnostic solution. Affera Inc., a US-based medical technology company, specializes in cardiac mapping and navigation systems, along with catheter-based cardiac ablation technologies.
Major companies operating in the ventricular assist device market report are Abiomed Inc, Abbott Laboratories, Medtronic, LivaNova PLC, Terumo Corporation, Berlin Heart GmbH, Cirtec, Jarvik Heart Inc., SynCardia Systems LLC., Calon Cardio-Technology Ltd., Huadong Medicine Co. Ltd., Shenzhen Hexin Zondan Medical Equipment Co. Ltd., Sun Medical Technology Research Corp., Boston Scientific Corporation, CorWave SA, CH Biomedical (USA) Inc., Evaheart Inc., BiVACOR Inc., ReliantHeart Inc., Cardiac Assist Inc., Heart Ware International, Braile Biomedica Ltd.
North America was the largest region in the ventricular assist device market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ventricular assist device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular assist device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary types of VADs include left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). LVADs, battery-operated mechanical pumps, help propel blood from the left ventricle to vital organs. They vary in design as transcutaneous or implantable devices and operate with different flow mechanisms such as pulsatile flow and continuous flow. These devices are used for various purposes including bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-recovery (BTR) therapy, and bridge-to-candidacy (BTC) therapy. End-users of VADs include hospitals, ambulatory surgical centers, and cardiology centers.
The ventricular assist device market research report is one of a series of new reports that provides ventricular assist device market statistics, including ventricular assist device industry global market size, regional shares, competitors with a ventricular assist device market share, detailed ventricular assist device market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular assist device industry. This ventricular assist device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The ventricular assist device market consists of sales of pulsatile and nonpulsatile LVADs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The ventricular assist device market size is expected to see rapid growth in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. Forecasted growth is due to increased demand for destination therapy, an aging population, higher healthcare spending, and greater awareness of heart failure treatments. Key trends include extending VAD lifespan, device miniaturization, advanced pump tech, improved safety/efficacy, reduced side effects, and percutaneously inserted VADs.
The surge in cardiovascular disorders globally is a driving force behind the expansion of the ventricular assist device market. Cardiovascular disorders, stemming from factors such as high blood pressure, smoking, high cholesterol, and inactivity, are on the rise. Noncontagious diseases such as diabetes, chronic respiratory illnesses, and heart attacks linked to hypertension contribute to the escalating prevalence of cardiovascular disorders. This trend underscores the heightened demand for ventricular assist devices, serving as crucial support systems for severely ill cardiac patients. For instance, in 2021, the World Health Organization reported that India was anticipated to account for one-fifth of global deaths from stroke and ischemic heart disease, particularly affecting younger adults. Moreover, projections indicate that around 12.1 million people in the U.S. are expected to experience atrial fibrillation (A-Fib) by 2030. The mounting prevalence of cardiovascular disorders is poised to drive significant demand for ventricular assist devices in the forecast period.
The increased awareness surrounding heart failure treatment is a pivotal factor expected to fuel the growth of the ventricular assist device market. Heart failure, characterized by the heart's diminished ability to effectively pump blood, can result from conditions such as coronary artery disease, heart attacks, high blood pressure, and heart muscle damage. The escalating awareness about heart failure treatments is anticipated to drive the adoption of ventricular assist devices as a means to address heart failure. Notably, the American Heart Association projects a 46% increase in heart failure diagnoses by 2030, surpassing 8 million individuals affected. As the number of people diagnosed with heart failure continues to rise, the heightened awareness of available treatment options is poised to be a key driver for the ventricular assist device market.
Technological advancements stand out as a prominent trend gaining traction in the ventricular assist device market. Companies within the ventricular assist device sector are directing their efforts toward the development of next-generation devices that enhance blood circulation. Key industry players are prioritizing the creation of ventricular assist devices with innovative technologies to gain a competitive advantage and fortify their market positions. An illustrative example is the initiative by CorWave, a France-based medical technology company, in 2021. CorWave successfully developed left ventricular assist device (LVAD) membrane pump technology. This LVAD membrane pump employs a pulse pump, utilizing electromagnetic pulses rather than a rotary pump, to facilitate blood movement, closely mimicking the natural pulsatile action of the heart.
The adoption of percutaneously inserted ventricular assist devices is gaining prominence in the market. Percutaneously inserted ventricular assist devices are non-pulsatile axial flow pumps positioned across the aortic valve, pumping blood from the left ventricle. These devices alleviate the load on the left ventricle, decrease myocardial oxygen consumption, enhance cardiac output, and reduce left ventricular end-diastolic pressure. As an example, in August 2022, Abiomed Inc., a US-based medical device company, introduced the Impella, a percutaneous VAD designed for eligible pediatric patients in the USA. The Impella device provides effective cardiac support to compensate for a failing left ventricle and can serve as an alternative to extracorporeal membrane oxygenation (ECMO) or complement other therapies to enhance hemodynamics.
In August 2022, Medtronic PLC, an Ireland-based medical device company, acquired Affera, Inc. for $925 million. This strategic acquisition broadens Medtronic's portfolio of cardiac ablation products, introducing their initial cardiac mapping and navigation platform. The platform includes radiofrequency ablation, focal pulsed field, and an integrated diagnostic solution. Affera Inc., a US-based medical technology company, specializes in cardiac mapping and navigation systems, along with catheter-based cardiac ablation technologies.
Major companies operating in the ventricular assist device market report are Abiomed Inc, Abbott Laboratories, Medtronic, LivaNova PLC, Terumo Corporation, Berlin Heart GmbH, Cirtec, Jarvik Heart Inc., SynCardia Systems LLC., Calon Cardio-Technology Ltd., Huadong Medicine Co. Ltd., Shenzhen Hexin Zondan Medical Equipment Co. Ltd., Sun Medical Technology Research Corp., Boston Scientific Corporation, CorWave SA, CH Biomedical (USA) Inc., Evaheart Inc., BiVACOR Inc., ReliantHeart Inc., Cardiac Assist Inc., Heart Ware International, Braile Biomedica Ltd.
North America was the largest region in the ventricular assist device market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ventricular assist device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular assist device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary types of VADs include left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). LVADs, battery-operated mechanical pumps, help propel blood from the left ventricle to vital organs. They vary in design as transcutaneous or implantable devices and operate with different flow mechanisms such as pulsatile flow and continuous flow. These devices are used for various purposes including bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-recovery (BTR) therapy, and bridge-to-candidacy (BTC) therapy. End-users of VADs include hospitals, ambulatory surgical centers, and cardiology centers.
The ventricular assist device market research report is one of a series of new reports that provides ventricular assist device market statistics, including ventricular assist device industry global market size, regional shares, competitors with a ventricular assist device market share, detailed ventricular assist device market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular assist device industry. This ventricular assist device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The ventricular assist device market consists of sales of pulsatile and nonpulsatile LVADs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ventricular Assist Device Market Characteristics3. Ventricular Assist Device Market Trends and Strategies32. Global Ventricular Assist Device Market Competitive Benchmarking33. Global Ventricular Assist Device Market Competitive Dashboard34. Key Mergers and Acquisitions in the Ventricular Assist Device Market
4. Ventricular Assist Device Market - Macro Economic Scenario
5. Global Ventricular Assist Device Market Size and Growth
6. Ventricular Assist Device Market Segmentation
7. Ventricular Assist Device Market Regional and Country Analysis
8. Asia-Pacific Ventricular Assist Device Market
9. China Ventricular Assist Device Market
10. India Ventricular Assist Device Market
11. Japan Ventricular Assist Device Market
12. Australia Ventricular Assist Device Market
13. Indonesia Ventricular Assist Device Market
14. South Korea Ventricular Assist Device Market
15. Western Europe Ventricular Assist Device Market
16. UK Ventricular Assist Device Market
17. Germany Ventricular Assist Device Market
18. France Ventricular Assist Device Market
19. Italy Ventricular Assist Device Market
20. Spain Ventricular Assist Device Market
21. Eastern Europe Ventricular Assist Device Market
22. Russia Ventricular Assist Device Market
23. North America Ventricular Assist Device Market
24. USA Ventricular Assist Device Market
25. Canada Ventricular Assist Device Market
26. South America Ventricular Assist Device Market
27. Brazil Ventricular Assist Device Market
28. Middle East Ventricular Assist Device Market
29. Africa Ventricular Assist Device Market
30. Ventricular Assist Device Market Competitive Landscape and Company Profiles
31. Ventricular Assist Device Market Other Major and Innovative Companies
35. Ventricular Assist Device Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Ventricular Assist Device Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ventricular assist device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ventricular assist device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Product: Left Ventricular Assist Devices (LVADs); Right Ventricular Assist Devices (RVADs); Biventricular Assist Devices (BIVADs)
2) By Type: Pulsatile Flow; Continuous Flow
3) By Design: Transcutaneous Ventricular Assist Devices; Implantable Ventricular Assist Devices
4) By Application: Bridge-To-Transplant (BTT) Therapy; Destination Therapy; Bridge-To-Recovery (BTR) Therapy; Bridge-To-Candidacy (BTC) Therapy
5) By End-users: Hospital; Ambulatory Surgical Centers; Cardiology Centers
Key Companies Mentioned: Abiomed Inc; Abbott Laboratories; Medtronic; LivaNova PLC; Terumo Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Abiomed Inc
- Abbott Laboratories
- Medtronic
- LivaNova PLC
- Terumo Corporation
- Berlin Heart GmbH
- Cirtec
- Jarvik Heart Inc.
- SynCardia Systems LLC.
- Calon Cardio-Technology Ltd
- Huadong Medicine Co. Ltd
- Shenzhen Hexin Zondan Medical Equipment Co. Ltd
- Sun Medical Technology Research Corp.
- Boston Scientific Corporation
- CorWave SA
- CH Biomedical (USA) Inc
- Evaheart Inc
- BiVACOR Inc
- ReliantHeart Inc
- Cardiac Assist Inc
- Heart Ware International
- Braile Biomedica Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 2.18 Billion |
| Forecasted Market Value ( USD | $ 3.5 Billion |
| Compound Annual Growth Rate | 12.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
